68.39
-0.54(-0.78%)
Currency In USD
| Previous Close | 68.93 |
| Open | 68.55 |
| Day High | 69.93 |
| Day Low | 66.95 |
| 52-Week High | 84.56 |
| 52-Week Low | 26.2 |
| Volume | 904,420 |
| Average Volume | 977,041 |
| Market Cap | 3.75B |
| PE | -15.61 |
| EPS | -4.38 |
| Moving Average 50 Days | 74.24 |
| Moving Average 200 Days | 51.68 |
| Change | -0.54 |
If you invested $1000 in Apogee Therapeutics, Inc. (APGE) since IPO date, it would be worth $3,221.38 as of February 21, 2026 at a share price of $68.39. Whereas If you bought $1000 worth of Apogee Therapeutics, Inc. (APGE) shares 2 years ago, it would be worth $1,976.59 as of February 21, 2026 at a share price of $68.39.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
GlobeNewswire Inc.
Jan 06, 2026 11:00 AM GMT
Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
GlobeNewswire Inc.
Jan 05, 2026 9:01 PM GMT
Webcast to be held Tuesday, January 6th at 8:00 a.m. ETSAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential